← Back to search
Literature record

Potential Role of Tumor-derived MIF in B-Cell Antigen Presentation in Lung Adenocarcinoma: Single-cell and TCGA Analyses.

PMID 41318120 | DOI 10.21873/anticanres.17874 · Anticancer research · 2025 · View on PubMed ↗

BACKGROUND/AIM: Lung adenocarcinoma (LUAD), a predominant subtype of non-small cell lung cancer (NSCLC), is characterized by a complex tumor microenvironment (TME) that drives immune evasion and contributes to variable clinical outcomes. This study investigates the role of tumor-derived macrophage migration inhibitory factor (MIF) on immune modulation and prognosis in LUAD. MATERIALS AND METHODS: Single-cell RNA sequencing (scRNA-seq) data from three LUAD tumors (E-MTAB-6149; 29,936 cells) were analyzed with Seurat to identify cell types and marker genes. Cell-cell communication was assessed using CellChat, and prognostic significance was evaluated in the TCGA-LUAD cohort with GEPIA2. RESULTS: Malignant cells showed the highest expression of MIF, which may interact with CD74 + CXCR4 + and CD74 + CD44 + receptor complexes on B cells, T cells, and myeloid cells, consistent with known MIF-mediated signaling pathways. A predominant B cell subset (59%) expressing CD74 or CXCR4 (termed as MIFR+ B cells) showed elevated expression of MHC class II genes (such as HLA-DRA and HLA-DPB1) and co-stimulatory genes (such as CD40 and CD83), indicating antigen-presenting cell (APC)-like functions. High MIF expression was associated with a poor prognosis in TRU-subtype LUAD [hazard ratio (HR)=2.5, p-value=0.029], while MIFR+ B cell signatures was correlated with improved survival. CONCLUSION: Tumor-derived MIF is associated with poor prognosis, likely by suppressing the immune system, but it also promotes the induction of APC-like B cells, which are associated with improved outcomes, highlighting its dual role in LUAD. These findings position MIF as a potential therapeutic target and suggest that MIFR+ B cells could serve as important prognostic markers.

Validated evidence

TypeEntitySource evidenceConfidenceExtractor
geneCD74“RESULTS: Malignant cells showed the highest expression of MIF, which may interact with CD74 + CXCR4 + and CD74 + CD44 + receptor complexes on B cells, T cells, and myeloid cells, consistent with known MIF-mediated signaling pathways.”0.98hgnc_dict_v1
geneCXCR4“RESULTS: Malignant cells showed the highest expression of MIF, which may interact with CD74 + CXCR4 + and CD74 + CD44 + receptor complexes on B cells, T cells, and myeloid cells, consistent with known MIF-mediated signaling pathways.”0.98hgnc_dict_v1
geneCD44“RESULTS: Malignant cells showed the highest expression of MIF, which may interact with CD74 + CXCR4 + and CD74 + CD44 + receptor complexes on B cells, T cells, and myeloid cells, consistent with known MIF-mediated signaling pathways.”0.98hgnc_dict_v1
geneHLA-DRA“A predominant B cell subset (59%) expressing CD74 or CXCR4 (termed as MIFR+ B cells) showed elevated expression of MHC class II genes (such as HLA-DRA and HLA-DPB1) and co-stimulatory genes (such as CD40 and CD83), indicating antigen-presenting cell (APC)-like functions.”0.98hgnc_dict_v1
geneHLA-DPB1“A predominant B cell subset (59%) expressing CD74 or CXCR4 (termed as MIFR+ B cells) showed elevated expression of MHC class II genes (such as HLA-DRA and HLA-DPB1) and co-stimulatory genes (such as CD40 and CD83), indicating antigen-presenting cell (APC)-like functions.”0.98hgnc_dict_v1
geneCD40“A predominant B cell subset (59%) expressing CD74 or CXCR4 (termed as MIFR+ B cells) showed elevated expression of MHC class II genes (such as HLA-DRA and HLA-DPB1) and co-stimulatory genes (such as CD40 and CD83), indicating antigen-presenting cell (APC)-like functions.”0.98hgnc_dict_v1
geneCD83“A predominant B cell subset (59%) expressing CD74 or CXCR4 (termed as MIFR+ B cells) showed elevated expression of MHC class II genes (such as HLA-DRA and HLA-DPB1) and co-stimulatory genes (such as CD40 and CD83), indicating antigen-presenting cell (APC)-like functions.”0.98hgnc_dict_v1
geneAPC“A predominant B cell subset (59%) expressing CD74 or CXCR4 (termed as MIFR+ B cells) showed elevated expression of MHC class II genes (such as HLA-DRA and HLA-DPB1) and co-stimulatory genes (such as CD40 and CD83), indicating antigen-presenting cell (APC)-like functions.”0.98hgnc_dict_v1
phenotypelung cancer“BACKGROUND/AIM: Lung adenocarcinoma (LUAD), a predominant subtype of non-small cell lung cancer (NSCLC), is characterized by a complex tumor microenvironment (TME) that drives immune evasion and contributes to variable clinical outcomes.”0.98phenotype_alias_lexicon_v2